You are here: Industry Insights > Market News > Breckenridge Announces Final ANDA Approval for Azacitidine for Injection

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Breckenridge Announces Final ANDA Approval for Azacitidine for Injection

americanpharmaceuticalreviewJune 27, 2017

Tag: Breckenridge , ANDA Approval , Azacitidine

Favorites

Breckenridge Pharmaceutical announced the FDA has granted final approval of its ANDA Azacitidine for Injection, 100mg per vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation. Breckenridge submitted the ANDA with its development and manufacturing partner Natco Pharma Limited. Breckenridge and Natco intend to launch its ANDA in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.

Previous:Boston Biomedical Announces Unblinding of Advanced Gastric/GEJ Cancer Phase 3 Trial

Next:FDA Approves Subcutaneous C1 Esterase Inhibitor to Treat Rare Genetic Disease

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Breckenridge Announces Final ANDA Approval for Azacitidine for Injection | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

Breckenridge Announces Final ANDA Approval for Azacitidine for Injection

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may like
More>>

Breckenridge Announces Final ANDA Approval for Azacitidine for Injection

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>